In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Association between hospital care quality and readmission among Japanese patients with heart failure. -From JROAD-DPC study-

Session Global trends in heart failure

Speaker Kazuhiro Nakao

Congress : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Abstract Session
  • FP Number : 6131

Authors : K Nakao (Suita,JP), S Yasuda (Suita,JP), T Noguchi (Suita,JP), M Nakai (Suita,JP), Y Sumita (Suita,JP), YM Nakao (Suita,JP), K Nishimura (Suita,JP), Y Miyamoto (Suita,JP), H Ogawa (Suita,JP)

Authors:
K Nakao1 , S Yasuda2 , T Noguchi2 , M Nakai3 , Y Sumita3 , YM Nakao3 , K Nishimura1 , Y Miyamoto3 , H Ogawa1 , 1National Cerebral & Cardiovascular Center - Suita - Japan , 2National Cerebral and Cardiovascular Center, Cardiovascular Medicine - Suita - Japan , 3National Cerebral and Cardiovascular Center, Center for Cerebral and Cardiovascular Disease Information - Suita - Japan ,

Citation:

Background: Measuring the process of care has become a widely used practice to improve a quality of care. Recently, some studies have demonstrated poor to no correlation between 30-day readmission rates and quality of care for heart failure (HF) among hospitalized HF patients. However the investigation about relationships of care quality for HF and 1 year outcome is limited.
Purpose: To investigate the relationship between quality of care in each hospitals and readmission among HF patients in Japan.
Methods: From Japanese Registry of All cardiac and vascular diseases (JROAD-DPC) database in 2014, 84,325 HF patients hospitalized to 741 certificated hospitals by Japanese Circulation Society were analyzed. A primary endpoint was readmission for HF in one year. Five performance measures were defined as prescription rate of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), prescription rate of beta blocker and prescription rate of spironolactone, measurement rate of echocardiography and measurement rate of B-type natriuretic peptide (BNP) during hospitalization. For each of the five measures, a composite score was created by giving points ranging from 1 to 4 from the lower quartile of rates, with the score ranging from 5 to 20 points. Hazard ratios (HR) indicating the effects of the performance measures were estimated using Cox proportional hazard models. Covariates included age, gender, Charson score, and NYHA class.
Results: In Japanese HF patients (age; 78.1 years old, man 52%), the HF readmission rate in one year was 14,520 (17.2%). The readmission rate decreased with higher quartiles of prescription rate in each medications and performance rates. The highest quartile of each measurements was significantly lower risk for readmission compared to the lowest quartile (ACE/ARB, adjusted HR 0.87 [95%CI, 0.83-0.91], p<0.001; beta-blocker, 0.83 [0.79-0.88], p<0.001; spironolactone, 0.88 [0.83-0.92], p<0.001; echocardiography, 0.90 [0.86-0.94], p<0.001; BNP, 0.92 [0.87-0.96], p<0.001). Kaplan-Meier curves showed that readmission rates were better among higher composite score, compared to lower composite score (Log-rank test=p<0.001). (Figure) Higher composite scores were associated with statistically significant risk reduction of 23% for HF readmission (HR 0.77, 95%CI [0.73-0.81], p<0.001).
Conclusion: The hospital performance measures were associated with a significant risk reduction of readmission in Japanese patients with HF.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are